HT
HRTX icon

Headlands Technologies’s Heron Therapeutics HRTX Stock Holding History

Headlands Technologies’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,287
Closed -$66.7K – 826
2025
Q4 		$66.7K Buy
51,287
+31,431
+158% +$38.8K 0.01% 640
2025
Q3 		$25K Sell
19,856
-63,496
-76% -$101K ﹤0.01% 593
2025
Q2 		$173K Sell
83,352
-9,206
-10% -$18.8K 0.02% 515
2025
Q1 		$204K Buy
92,558
+66,886
+261% +$130K 0.02% 456
2024
Q4 		$39.3K Sell
25,672
-24,024
-48% -$38.9K ﹤0.01% 849
2024
Q3 		$98.9K Sell
49,696
-40,799
-45% -$97.4K 0.01% 675
2024
Q2 		$317K Buy
90,495
+79,609
+731% +$245K 0.03% 375
2024
Q1 		$30.2K Buy
+10,886
New +$27.4K 0.01% 828
2023
Q3 		– Sell
-2,643
Closed -$3.07K – 1046
2023
Q2 		$3.07K Buy
+2,643
New +$4.71K ﹤0.01% 700

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Headlands Technologies's HRTX Position: Q1 2026 in Review

Headlands Technologies sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 51,287 shares — an estimated $66.7K sold.

Headlands Technologies first reported a position in HRTX in Q2 2023 and held it in 9 quarters. The position peaked at $317K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Headlands Technologies reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Headlands Technologies sold 51,287 Heron Therapeutics shares in Q1 2026, an estimated $66.7K.
  • Headlands Technologies first reported a position in Heron Therapeutics in Q2 2023 and held it in 9 quarters.
  • Headlands Technologies's Heron Therapeutics position peaked at $317K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.